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ABSTRACT
Interleukin (IL)-1 Regulates Ozone-induced Nerve Growth Factor (NGF) and Substance P
(SP) Release in Bronchoalveolar Lavage Fluid (BALF) in Mice
Joshua S. Barker

Previous studies show that both IL-1 and NGF increase synthesis of SP in airway neurons
after either direct application or ozone exposure. We hypothesize that NGF mediates ozoneinduced IL-1 effects on SP, similar to the pathway described for sympathetic neurons in culture.
The current study specifically focuses on the effect of ozone on IL-1, NGF, and SP levels in
mice BALF and if these mediators can be linked in an inflammatory-neuronal cascade in vivo.
The experiments demonstrate in vivo ozone exposure induces an increase of all three proteins in
mouse BALF and that both ozone-induced increases in NGF and SP are mediated by the
inflammatory cytokine IL-1. Even though these findings did not definitely link NGF as the
mediator of IL-1 effects on SP, it did not conclusively eliminate this possibility. These data did
indicate that IL-1 is an early mediator of ozone-induced increase in NGF and SP release in mice
in vivo.
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I. INTRODUCTION
Although it has been shown in numerous animal models (i.e., mice, rats, guinea pigs and
humans) that irritant exposure, specifically ozone, can induce airway inflammation and airway
hyperresponsiveness (AHR), the causative mechanism(s) has not been definitely determined.
Even so, each of the chemical mediators IL-1, NGF, and SP have been shown to be increased
after ozone exposure and have also been shown to separately participate in the resulting ozoneinduced AHR.
Exogenous application or increases of any one of these three proteins have been shown to
induce AHR by themselves. These mediators have also been shown to exert effects on each
other in the airways. For example, the inflammatory cytokine interleukin 1 (IL-1) induces the
expression of the neurotrophin Nerve Growth Factor (NGF) and the tachykinin Substance P (SP).
Furthermore, exogenous application of NGF increases the synthesis of SP in normal SPcontaining neurons and induces SP production in neurons normally devoid of SP. These
correlations suggest a possible inflammatory-neuronal cascade that would account for the
translation of the ozone insult into the ensuing AHR.
Even though there has been extensive research into the specific down-stream effects of
ozone exposure and its mediators including IL-1, NGF, and SP, there has not been an in vivo
study investigating the possible linking of these mediators. Given the significant role each
mediator serves in ozone-induced AHR, this is an important question. The present study attempts
to elucidate the in vivo causative relationships of these chemical intermediaries. The results
demonstrate that the inflammatory cytokine IL-1 mediates the majority of the ozone-induced
increases of NGF and SP. The findings suggest that NGF contributes to the ozone-induced
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increase in SP, though this needs further investigation. Overall, the findings support the
hypothesis that ozone initiates an inflammatory-neuronal cascade starting with IL-1 production
which triggers NGF release leading to increased SP production.
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II. BACKGROUND
A. Ozone (O 3 )
As the primary constituent of photochemical smog, ground level ozone is a major urban
pollutant and is regulated by the Environmental Protection Agency through the Clean Air Act
(United States Environmental Protection Agency, 1990). It is not directly emitted but is formed
as a byproduct of fossil fuel combustion from sources such as automobiles, power plants, and the
manufacturing industry. The combustion of hydrocarbons releases volatile organic compounds
and nitrogen oxides that undergo a photochemical reaction resulting in the ground level matrix of
particulate matter and ozone – photochemical smog. Such air pollution is present in virtually all
cities but extremely prevalent in very sunny, warm, dry areas with a large number of
automobiles, especially where the warm upper air prevents vertical circulation (Baird, 1999).
Examples of these ozone-prone areas in the United States are Houston, Los Angeles,
Sacramento, San Francisco, and Chicago (United States Environmental Protection Agency,
2006).
Ozone functions as an oxidizing agent and causes clinical symptoms in humans including
shortness of breath, chest pain, wheezing, coughing, and the exacerbation of asthma (Menzel,
1984). There is a close correlation between high ozone concentrations and increased hospital
visits resulting from respiratory illnesses, specifically asthma (Burnett et al., 1994; Thurston et
al., 1992; Romieu et al., 1995; Yang et al., 2003). Effects from exposure to ozone are both
transient and prolonged. A recent New England Journal of Medicine article demonstrates a
significant increase in respiratory related death rates with increased long-term ozone
concentration exposure. The study shows the risk of a respiratory related death is more than
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three times as great in the highest ozone concentration metropolitan areas as compared to those
with the lowest ozone concentration (Jerret et al., 2009).
The physiological effects of ozone exposure have been shown in numerous animal
models including mice (Mustafa et al., 1982), rats (Evans et al., 1988), guinea pigs (Gordon et
al., 1984), dogs (Matsui et al., 1991), and in human subjects (Horstman et al., 1990).
Pathological changes from ozone exposure include damage to the airway epithelium, pulmonary
inflammation and airway hyperresponsiveness (Hazbun et al., 1993; Leikauf et al., 1995; Wu and
Lee, 1999; Beckett et al., 1991; Sterner-Kock et al., 2000). The resultant inflammatory response
is characterized by neutrophil influx into the trachea and bronchoalveolar space (which is
different than eosinophillic influx in allergen induced inflammation) and increased serum protein
levels in lavage fluid (Pino et al., 1992; Aris et al., 1993; Basha et al., 1994; Devlin et al., 1996;
Krishna et al., 1998; DeLorme et al., 2002). There is also increased smooth muscle response to
broncho-constricting agonists, the characteristic feature of airway hyperresponsiveness (AHR)
(Hiltermann et al., 1995). The definitive causal relationship between the pulmonary
inflammation and the resulting airway hyperresponsiveness is unclear, however much is known
about the downstream effects of ozone exposure, including the induction and release of many
inflammatory mediators, including cytokines, chemokines, neurotrophins, as well as the release
of tachykinins, all of which could produce airway inflammation and AHR.
B. Interleukin-1 (IL-1)
One possible mediator of ozone induced airway hyperresponsiveness and inflammation is
the pro-inflammatory cytokine IL-1. Even though the IL-1 family was originally discovered
over fifty years ago, it was not discovered until 1985 that IL-1 consisted of two separate entities
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– IL-1α and IL-1β (March et al., 1985).

IL-1α is biologically active as both the precursor pro-

IL-1α form and as the mature protein (Huising et al., 2004) and is primarily an intracellular
mediator (Allan et al., 2005). IL-1β is inactive in its precursor form and is secreted by an
undetermined pathway (Thornberry et al., 1992). Even though both are encoded by separate
genes, they share high sequence homology and bind to the membrane bound type I IL-1 receptor
(IL-1R1) (Sims et al., 1988). The effects of IL-1α and IL-1β can be blocked by a naturally
occurring competitive IL-1R antagonist (IL-1Ra) produced and secreted by the same cells that
produce IL-1. The IL-1Ra binds to IL-1R1 but does not initiate any signal transduction
(Hannum et al., 1990).
IL-1 has been shown to be a major component in irritant induced AHR (Barnes et al.,
1998; Park et al., 2004; Johnson et al., 2005) and can induce AHR alone whether from injection
in guinea pigs and rats or by in vitro application on human isolated bronchi (Frossard et al.,
2005). IL-1 has also been shown to increase other possible mediators of AHR, including nerve
growth factor (NGF) and substance P (SP). IL-1 has been shown to increases the synthesis and
release of NGF from airway structural cells including cultured human airway epithelial cells
(Pons, et al 2001; Fox et al., 2001), bronchial smooth muscle cells (Freund et al., 2002; Kemi et
al., 2006), and pulmonary fibroblasts (Olgart and Frossard, 2001). Conversely, in cultured
human pulmonary fibroblasts (Olgart and Frossard, 2001) and epithelial cells (Pons, et al., 2001)
IL-1 mediated increases in NGF can be reduced by application of anti-inflammatory drugs, such
as corticosteroids. It has been suggested that IL-1 induction of NGF transcription could be
caused by the activation of inflammatory transcriptional factors, like activated protein-1 (AP-1)
(Freund et al., 2002), since the AP-1 responsive element is a component of the NGF gene
promoter (Lee et al., 1987; Cartwright et al., 1992). Further proof that the AHR effect of IL-1β
5

may be in part mediated by NGF is the evidence that pre-treatment with an NGF blocking
antibody can abolish the IL-1 β-induced AHR in isolated human bronchial smooth muscle strips
(Frossard et al., 2005).
Specific effects of IL-1β on airway neurons have also been reported. In ferrets,
exogenous IL-1β increases the number of SP-positive neurons of airway ganglia and SP
innervation of airway smooth muscle as well as inducing SP production in intrinsic airway
neurons which do not normally express it (Wu et al., 2002). In addition, application of IL-1 Ra
diminished ozone-enhanced SP levels in the airway and decreases AHR in ferrets (Wu et al.,
2008). These studies demonstrate that IL-1 modulates SP expression in airway neurons and
participates in ozone-induced AHR.
C. Nerve Growth Factor (NGF)
NGF was originally discovered by Rita Levi-Montalcini and co-workers in the 1960’s as
a sarcoma-derived substance that stimulated the outgrowth of dorsal root ganglion neurons and is
now recognized to be a survival and differentiating factor for neural crest derived sensory
neurons, as well as, sympathetic and basal forebrain cholinergic neurons (Levi-Montalcini and
Angeletti, 1968; Sofroniew et al, 2001). Because of this, it is included in the neurotrophin
family of peptides, along with brain-derived neurotrophic factor (BDNF), and neurotrophins
(NT) -3, -4, -5, and -6 (Frossard, et al 2004), all of which have been established as playing
critical roles in vertebrate nervous and cardiovascular development (Tessarollo, 1998; Huang and
Reichardt, 2001; Chao, 2003).
NGF is composed of an α, β, and γ subunit with the γ subunit being responsible for its
biological activity (Bax, et al., 1993). The actions of NGF are dictated by its binding to one of
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two cell surface receptors: (1) the high-affinity tropomyosin-receptor tyrosine kinase A (TrkA),
or (2) the low affinity receptor p75, which also interacts with BDNF, NT-3,-4, and -5 (Lindsay
and Harmar, 1989; Hempstead, 2002). Of the two receptors, only TrkA uses tyrosine kinase as
part of its signal transduction. Among the group of neurotrophins NGF has the highest binding
affinity for the TrkA receptor (Ibáñez et al., 1998). Binding of NGF to the TrkA receptor
induces its homodimerisation and autophosphorylation, activating many different cell-signaling
pathways (Kaplan et al, 1991). The end result is dependent on the specific cell type and
subsequent pathways activated and can result in cell proliferation, differentiation, and survival,
or apoptosis inhibition (Frossard, et al, 2004). More specifically, NGF has been shown to
regulate neuronal phenotypic traits such as stimulus responsiveness (Lewin and Mendell, 1993),
response to neuronal injury (Olson et al., 1994) and neuropeptide expression (Kessler and Black,
1980; Otten et al., 1980; Hunter et al., 2000).
Recently, NGF has been shown to not only be a mediator of inflammation resulting in
AHR in various in vitro and in vivo animal models (Woolf, et al, 1994; Braun et al., 1998;
Nassenstein, et al, 2004; Bachar, et al, 2004; de Vries, et al 2006) but can specifically cause
AHR apparently through direct action on airway smooth muscle (Friberg et al, 2001; de Vries et
al., 1999). NGF is produced and released by various inflammatory and structural cells in the
airways, including mast cells, eosinophils, neutrophils, monocytes/macrophages, bronchial
epithelial and smooth muscle cells, and pulmonary fibroblasts (for review see Frossard et al,
2004). Serum NGF levels are increased in patients with asthma compared to those nonasthmatics (Bonini et al., 1996) and NGF is elevated in bronchoalveolar lavage fluid of
asthmatics (Olgart Höglund et al., 2002). Further evidence of NGF’s role in AHR has been
shown by AHR being induced by tissue specific over-expression of NGF in the airways of
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transgenic mice (Hoyle et al., 1998; Päth et al., 2002), and by pre-treatment with anti-NGF
antibodies in mice and guinea pigs to reduce allergen induced AHR (Braun et al., 1998; de Vries
et al., 2002).
NGF increases the intracellular level and release of SP from a wide range of neurons
(Adler et al., 1984; Lindsay and Harmar, 1989; Vedder et al., 1993; Cho et al., 1996; Hoyle,
2003; Malcangio et al., 2000; Skoff et al., 2003;) and causes the phenotypic switch to SP
production in airway sensory neurons derived from the nodose ganglia which do not typically
express SP (Hunter et al., 2000).
D. Substance P (SP)
The final link between ozone exposure and the subsequent inflammation and AHR could
be SP. SP is a member of the tachykinin family and was first discovered over 80 years ago (von
Euler and Gaddum, 1931). It primarily binds with high affinity to the neurokinin 1 (NK 1 )
receptor but does also bind, with low affinity, to the NK 2 and NK 3 receptors (Maggi et al., 1993;
Regoli et al., 1994; Severini et al., 2002). The NK 1 receptor is a seven-transmembrane G-protein
coupled receptor and activates a phosphatidylinositol-calcium second messenger system. It is
important to realize that release of tachykinins from sensory nerves in the airways requires a
stimulus of chemical origin.
With regard to airway innervation, SP is synthesized by translation of the
preprotachykinin mRNA in nerve cell bodies of sensory neurons located in the nodose and
jugular ganglia and, in response to exposure to ozone and other irritants, released from nerve
terminals located in the airway epithelium, smooth muscle, and mucosal blood vessels (Lee et
al., 1979; Koto et al., 1995; Joad et al., 1996). SP release has also been documented from
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intrinsic airway neurons (Wu et al., 2001 and 2003) and has been shown to be a central mediator
of ozone-induced AHR (Lee et al., 1979; Koto et al., 1995; Joad et al., 1996; Wu et al., 1997;
Graham et al., 2001). SP nerves are relatively prevalent in the airways as evident by
radioimmunoassay and immunohistochemistry showing SP nerves beneath and within the
epithelium, around blood vessels, and submucosal glands and within the bronchial smooth
muscle layer (Lundberg et al., 1984; Luts et al., 1993). The NK 1 receptor is expressed in the
airway epithelium, the submucosa, endothelium of blood vessels, goblet cells, surfaces of
inflammatory cells (Chu et al., 2000) and in airway smooth muscle cells (Maghni et al., 2003).
Ultimately, SP induces AHR by increasing the cholinergic sensitivity of airway smooth muscle
(Tanaka and Grunstein, 1984) and has been shown to facilitate acetylcholine release from postganglionic nerves in many species including guinea pigs, rabbits, mouse and humans (Joos et al.,
1988; Hall et al., 1989; Black et al., 1990; Colasurdo et al., 1995; Tournoy et al., 2003).
Blocking the action of SP reverses airway hyperreactivity. Aerosolized neutral
endopeptidase, the enzyme responsible for neutralizing released SP, diminishes ozone-induced
AHR (Nadel, 1991; Murlas et al., 1992). Depletion of SP by capsaicin treatment prior to ozone
exposure prevents AHR, by decreasing the bronchial influx of neutrophils and subsequent
bronchial edema (Tepper et al., 1993; Kaneko et al., 1994; Koto, et al, 1995). Furthermore, it
has been shown in vivo that NK 1 receptor antagonist attenuates both the ozone-enhanced airway
responses in ferret trachea (Wu et al., 2001 and 2003) and the NGF-induced AHR in guinea pigs
(de Vries, et al., 1999). This is important in alluding to NGF/TrkA-mediating SP levels in the
airways. Additional proof pointing to this possible cascade is provided by a recent study,
showing an increase in SP as well as trkA in large-diameter neurons in the nodose and jugular
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ganglia after injection of NGF in the lower airways of mice, suggesting trkA mediates SP
induction of neurogenic airway inflammation (Dinh et al., 2004)
E. Statement of Problem
The chemical mediators IL-1, NGF, and SP are increased after ozone exposure and have
been shown to participate in the resulting AHR. In addition, it has also been demonstrated that
SP can be induced by both exogenous application of the pro-inflammatory cytokine IL-1 or the
neurotrophin NGF and that NGF itself can be induced by exogenous application of IL-1. These
findings suggest a possible inflammatory-neuronal cascade that would translate the ozone insult
to the ensuing airway pathologies.
F. Hypothesis
The hypothesis that will be studied is that ozone exposure induces airway
hyperresponsiveness (AHR) by increasing the level of interleukin-1 (IL-1), which in turn
increases the release of nerve growth factor (NGF), which ultimately enhances substance P (SP)
release (Figure 1).
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Figure 1. A possible illustration of the proposed inflammatory-neuronal cascade for airway hyperresponsiveness induced by ozone exposure and investigated by this project. Exposure to ozone injures
bronchial epithelial cells (1.), causing them to release IL-1 (2.). This in turn, allows IL-1 to bind to its
receptor, IL-1R, on the surface of bronchial (3a) and vascular (3b) epithelial cells. The binding of IL-1 to
the IL-1R of the bronchial epithelial cells releases NGF (4.), while the binding of IL-1 to IL-1R on the
vascular endothelial cells allows for the passage of polymorhphonuclear cells (PMN) to pass in to the
bronchial space, bind IL-1 with their own IL-1R and release NGF (4.). NGF from either/both sources
binds to trkA receptors on substance P producing neurons, increasing the production and release of
substance P (5.).
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G. Rationale
The rationale of these experiments was two-fold:
(1) Test in vivo the above proposed mechanism to determine if an inflammatory-neuron
cascade pathway involving IL-1, NGF, and SP is responsible for irritant induced airway
hyper-responsiveness
(2) Establish in a murine model the responses we have already characterized using an in vivo
ferret model. The murine model would provide more cellular manipulations and
investigative techniques (i.e., transgenic mice models, small interfering-RNA) for future
studies.

H. Specific Aims and Expected Results
1. Determine the effect of ozone on the concentrations of IL-1, NGF, and SP in BALF from an
in vivo murine exposure model.
2. Determine if IL-1Ra is able to diminish the expected ozone-induced increases of NGF and SP
in mouse BALF.
3. Determine if either a tyrosine kinase inhibitor K252a or an anti-NGF antibody will diminish
the expected ozone-induced increase of SP in mouse BALF.
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The following table is a summary of our experimental design and the expected results:

Proposed Mechanism

Experimental
Design

Ozone

Ozone

+

IL-1

NA



IL-1



NGF



SP

Added

Expected
IL-1Ra + Ozone

+

Results
K252a + Ozone

+

Anti-NGF +
Ozone

+

III. MATERIALS AND METHODS
A. Animal use and anesthetics
Adult (8 weeks old) male ICR mice (Harlan Laboratories, Inc) were housed four per
cage, under controlled light-cycle (12 hr. light/12 hr. dark) and temperature (22-24ºC)
conditions, with access to food and water ad libitum in the West Virginia University animal
facility. Mice were anesthetized with a ketamine/xylazine mixture in a single intraperitoneal
injection before intratracheal (i.t.) instillations. Animals were sacrificed 24 hours after ozone/air
exposure or i.t. instillations with a lethal dose of sodium pentobarbital (200mg/kg). All
procedures were approved through ACUC review under Protocol #06-0501.
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B. I.T. instillation of IL-1 or IL-1 receptor antagonist (IL-1Ra)
Mice were anesthetized with a dosage of ketamine/xylazine (25mg/kg and 2mg/kg,
respectively) mixture in a single i.p. injection. An 21-guage steel tube, 4.7 cm in length
connected to a 1 ml tuberculin syringe filled with either 20µl of IL-1β (200µl/ml; Santa Cruz
Biotechnology, Inc.), IL-1Ra (200ng/ml; Amgen, Inc.), or saline. The tube was inserted through
the oral cavity and pharynx into the trachea and the solution was instilled into the trachea. One
hour after the last IL-1Ra or saline instillation, mice were exposed in vivo to 2ppm ozone for
three hours. The mice were allowed to recover from the anesthetic and returned to the animal
facility until the following day.
C. I.T. instillation of the tyrosine kinase inhibitor K252a or anti-NGF antibody
Mice were anesthetized and underwent identical ozone exposure as above. Mice received
a 20µl intratracheal (i.t.) instillation of anti-NGF antibody (200µg/ml; Santa Cruz
Biotechnology, Inc.) or saline one, two, or four hours before ozone exposure. The tyrosine
inhibitor K252a (100µg/ml; Alexis Biochemicals; Sand Diego, CA) was administered in two
different ways. Initially, the K252a was dissolved in 100% dimethyl sulfoxide (DMSO) and
administered to mice by i.t. instillation two or four hours prior to ozone exposure. For a second
set of experiments, the inhibitor was dissolved in a 10% DMSO in saline solution and then
administered by i.t. instillation to the mice at four hours prior to ozone exposure. The last
experimental design utilized i.t. instillation of the K252a DMSO/PBS solution twelve and three
hours prior to ozone exposure and then immediately after the exposure; a total of three separate
i.t. instillations of K252a were given to each mouse.
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D. In vivo ozone exposure
All in vivo ozone exposures were done at 2 ppm in a 12x12 inch stainless steel and glass
chamber for three hours. Ozone was produced by passing hospital-grade air through a drying
and high-efficiency particle (HEPA) filter and then through an ultraviolet light source. The
ozone concentration in the chamber was measured by chemiluminescence with a calibrated
ozone analyzer (OA 350-2R model; Forney Corporation; Carrolton, TX). Air control animals
were exposed to filtered air using procedures identical to those above, except ozone was not
delivered to the mixing chamber. The ozone exposure apparatus has been described in detail
elsewhere (Wu et al., 2002).
E. Bronchoalveolar lavage fluid (BALF) collection
Twenty-four hours after ozone/air exposure or the final i.t. instillation, mice were
anesthetized with a single dose of sodium pentobarbital injection (i.p). The lungs were lavaged
with 3ml PBS (1.5ml, twice) through a tracheal cannula and the BALF was placed into 15ml
conical tubes with 30µl of the proteinase inhibitor phosphoramidon (1x10-4 µM) to inhibit
neutral endopeptidases which degrade SP. The collected BAL fluid was centrifuged at 1,500
rpm for 10-12 min. at 15ºC. The supernatant was aliquoted and frozen at -80ºC for subsequent
assays.
F. IL-1 Enzyme-Linked Immunosorbent Assay
The BALF supernatant samples (initial 3ml) were frozen at -80ºC. The concentration of
IL-1 (31-100pg/ml) in each sample was assayed using the mouse IL-1β/IL-1F2 DuoSet® ELISA
Development System (R&D Systems, Inc; Minneapolis, MN) according to the manufacturer’s
instructions. IL-1 was detected using an anti-body sandwich format in 96-well plates (Figure 2).
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Each well was initially coated with 100µl of rat anti-mouse IL-1β and incubated overnight
followed by 1 hr. incubation with blocking buffer (300µl/well) to prevent non-specific binding.
Either 100µl of lavage supernatant or 100µl of NGF standard (31-1000 pg/ml) was added to each
well. The plate was incubated for 2 hr. followed by 2 hr. incubation with biotinylated goat antimouse IL-1β (100µl/well). For color development, streptavidin conjugated to horseradish
peroxidase was added to each well (100µl) followed by a TMB solution, which reacts with the
peroxidase-labeled conjugates to develop a blue color. The reaction was stopped after 10 min.
with 2N sulfuric acid (50µl/well) causing the blue to change to yellow upon acidification. The
absorbance of each well was measured at 450nm, with a wavelength correction at 540nm, on a
Spectra Max 340pc plate reader (Molecular Devices, Sunnyvale, CA). The concentration of IL-1
in each lavage sample was extracted from an IL-1 standard curve. All samples were run in
triplicate, and as a negative control, a PBS sample was run with each assay.
G. NGF Enzyme-Linked Immunosorbent Assay
The BALF supernatant samples (initial 3ml) were frozen at -80ºC. The concentration of
NGF (7.8-1000 pg/ml) in each sample was assayed using the NGF Emax ImmunoAssay System
(Promega, Madison, WI) according to the manufacturer’s instructions. NGF was detected using
an antibody sandwich format in 96 well plates (Figure 2). Each well was initially coated with
100µl of anti-NGF pAb and incubated overnight followed by 1 hr. incubation with blocking
buffer (200µl/well) to prevent non-specific binding. Either 100µl of lavage supernatant or 100µl
of NGF standard (7.8-1000 pg/ml) was added to each well. The plate was incubated for 6 hr.
followed by an overnight incubation with anti-NGF mAb (100µl/well). For color development
an anti-rat IgG, horseradish peroxidase conjugate antibody was added to each well (100µl)
followed by a TMB solution, which reacts with the peroxidase-labeled conjugates to develop a
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blue color. The reaction was stopped after 10 min. with 1N hydrochloric acid (100µl/well)
causing the blue to change to yellow upon acidification. The absorbance of each well was
measured at 450nm on a Spectra Max 340pc plate reader (Molecular Devices, Sunnyvale, CA).
The concentration of NGF in each lavage sample was extracted from an NGF standard curve.
All samples were run in triplicate, and as a negative control, a PBS sample was run with each
assay.

Figure 2. Illustration of a sandwich ELISA. (1) ELISA plate is coated with capture antibody.
(2) Sample is added and the respective antigen present binds to capture antibody. (3) Biotinconjugated secondary detection antibody is added and binds to the antigen captured by the first
antibody. (4) Streptavidin-HRP is added and binds to the biotin conjugated detection antibody.
(5) Colored product is formed in proportion to the amount of antigen is present in the sample.
The reaction is stopped by acid addition and absorbance measured at 450 nm.

H. SP Enzyme-Linked Immunosorbent Assay
The BALF supernatant samples (initial 3ml) were frozen at -80ºC. The concentration of
SP (39-2500 pg/ml) in each sample was assayed using the Parameter Substance P Assay (R&D
Systems, Inc; Minneapolis, MN) according to the manufacturer’s instructions. SP was detected
using a competitive binding technique in 96 well goat anti-mouse microplate (Figure 3). Either
50µl of lavage supernatant or SP standard (39-2500 pg/ml) was added to each well. Each well
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then received 50µl of the primary antibody solution (mouse monoclonal anti-SP) and 50µl of SP
conjugated with horseradish peroxidase. After a 3 hr. incubation and wash, 200µl of TMB was
added for color development. The reaction was stopped after 30 min. with 2N sulfuric acid
(50µl/well) causing the blue to change to yellow upon acidification. The absorbance of each
well was measured at 450nm, with a wavelength correction at 540nm, on a Spectra Max 340pc
plate reader (Molecular Devices, Sunnyvale, CA). The concentration of SP in each lavage
sample was extracted from an SP standard curve. All samples were run in triplicate, and as a
negative control, a PBS sample was run with each assay.

Figure 2. Illustration of a competitive ELISA. (1) ELISA plate is pre-coated with capture
antibody. (2) Sample and Tracer antigen (HRP-conjugated SP) are added and compete for a
limited number of antigen binding sites present on the capture antibody. (3) Excess sample
and tracer antigen are rinsed off. (4) Colored product is formed in an inverse proportion to the
amount of antigen present in the sample. The reaction is stopped by acid addition and
absorbance measured at 450 nm.
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I. Statistical Methods
In all studies, differences among groups were determined using a two-tailed Student’s TTest using Microsoft Excel software. Mean and standard error is reported for each value.
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IV. RESULTS
1. Effect of ozone on IL-1, NGF, & SP in BALF
Experiments were conducted to evaluate the effects of ozone on IL-1, NGF, and SP levels
in bronchoalveolar lavage fluid (BALF) as compared to control animals exposed to air. BALF
was collected 24 hours after ozone/air exposure. Ozone exposure significantly increased levels
of IL-1 (210.3 ± 38 pg/ml, n=4), NGF (3230.7 ± 1039 pg/ml, n=6), and SP (4280.3 ± 635 pg/ml,
n=4) when compared to air controls (114.6 ± 9.8 pg/ml (n=6), 753.3 ± 217 pg/ml (n=5), and
1488.7 ± 459 pg/ml (n=3), respectively) (P ≤ 0.05, Figure 4).

Figure 4. Effect of ozone exposure on the levels of (A) IL-1(air n=6, ozone n=4), (B) NGF (air n=5,
ozone n=6), and (C) substance P (air n=3, ozone n=4) in mouse bronchoalveolar lavage fluid as measured
by ELISA. Values are means ± SE. * Significant difference between air and ozone exposed animals, P =
0.03. ** Significant difference between air and ozone exposed animals, P = 0.007.
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2. Effect of exogenous IL-1 on NGF and SP levels in BALF
Experiments were conducted to determine if intra-tracheal (i.t.) instillation of exogenous
IL-1 would increase NGF and SP in BALF collected 24 hours after instillation and compared to
control animals which received a saline i.t. instillation. It is important to note that neither the
experimental nor control animals were exposed to ozone. NGF levels significantly increased
from 1349.7 ± 463 pg/ml in the control animals to 3424.8 ± 915 pg/ml in IL-1 treated animals
(n=5 both groups) (P≤0.04, Figure 5A). BALF from IL-1 treated animals also contained a very
significantly higher concentration of SP (4970.7 pg/ml, n=6) than BALF collected from saline
controls (1557.8 pg/ml, n=6) (P≤0.0005, Figure 5B)

Figure 5. Effect of IL-1 treatment on the levels of (A) NGF (n=5) and (B) substance P (n=6)
in mouse bronchoalveolar lavage fluid as measured by ELISA. Values are means ± SE. *
Significant difference between treated and untreated animals, P = 0.04. ** Significant
difference between treated and untreated animals, P = 0.0005.
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3. IL-1 Ra reduces ozone induced NGF and SP levels in BALF
Animals that were administered an i.t. instillation of IL-1 Ra prior to ozone exposure had
significantly decreased levels of both NGF (2070 ± 371 pg/ml, n=6) and SP (1852.2 ± 567
pg/ml, n=5) in BALF than in control animals that received an i.t. instillation of saline prior to
ozone exposure (3696.5 ± 681 pg/ml, n=6 and 4959 ± 1038 pg/ml, n=4, respectively). (Figure 6)

Figure 6. Effect of IL-1 receptor antagonist on the levels of (A) NGF (n=6) and (B) substance P
(i.t. saline, n=4, i.t. IL-1Ra n=5) in mouse bronchoalveolar lavage fluid as measured by ELISA.
Values are means ± SE. * Significant difference between treated and untreated animals, P=0.03.
** Significant difference between treated and untreated animals, P = 0.01.

4. Tyrosine kinase inhibitor K252a failed to effect SP levels in BALF
K252a was first dissolved in DMSO and administered to mice via an i.t. instillation two
and four hours before ozone exposure while control groups were administered an instillation of
DMSO at the same time prior to ozone exposure. There was no significant difference between
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the two hour (4568.8 ± 447.2 pg/ml, n=6) or four hour K252a pre-treatment groups (4405.4 ±
972 pg/ml, n=5) and their saline control groups (4871.4 ± 315.3 pg/ml, n=5 and 3927.7 ± 1515
pg/ml, n=3, respectively) (Figure 7, A and B).
The next two experiments used K252a dissolved in a 10% DMSO in PBS solution.
Initially mice were given an i.t. instillation once four hours prior to ozone exposure with control
mice receiving the 10% DMSO in PBS solution only. As before, there was no significant
difference between K252a pre-treated animals (4130.5 ± 1019.6 pg/ml, n=4) and the control
animals (4233.3 ± 2008.3 pg/ml, n=3) (Figure 7C).
In the following experiment, animals received an i.t. instillation of the K252a solution 12
hours and 3 hours prior to ozone exposure and then re-administered K252a immediately after the
ozone exposure. Control animals were given the DMSO/PBS vehicle solution at the same time
prior to and after their ozone exposure. Again, there was no significant difference between the
K252a treated group (5498.7 ± 21.1 pg/ml, n=5) and the vehicle treated group (5560.1 ± 2.3
pg/ml, n=5) (Figure 7D).
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Figure 7. Effect of the tyrosine kinase inhibitor K252a on the levels of substance P in mouse
bronchoalveolar lavage fluid as measured by ELISA. (A) K252a instilled two hours prior to
ozone exposure (DMSO, n=5, K252a, n=6). (B) K252a instilled four hours prior to ozone
exposure (DMSO, n=3, K252a, n=5). (C) K252a in 10% DMSO/PBS delivered four hours
before exposure (DMSO/PBS, n=3, K252a, n=4). (D) Instillation of K252a in 10% DMSO/PBS
twelve and three hours prior to and immediately after ozone exposure (n=5). Values are means ±
SE.
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5. Effect of anti-NGF antibody application on SP levels in BALF
Experimental groups of mice were administered an i.t. instillation of anti-NGF antibody
one, two or four hours prior to ozone exposure. Control animals received a saline i.t. instillation
at matched times before ozone exposure. Neither the one hour antibody pre-treatment group
(3977.6 ± 192.7 pg/ml, n=5) nor the two hour antibody pre-treatment group (5472 ± 172.8 pg/ml,
n=5) were significantly different from the saline control groups (3877.5 ± 867.4 pg/ml, n=4 and
5290.5 ± 396.9 pg/ml, n=4, respectively) (Figure 8, A and B). Even though the difference
between the four hour antibody pre-treatment (6229.8 ± 67.4 pg/ml, n=5) and the matched saline
control group (6505.5 ± 41.4 pg/ml, n=4) appeared to be minimal (275.7 pg/ml), it was
significantly different (P=0.01) (Figure 8C).
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Figure 8. Effect of anti-NGF antibody on the level of substance P in mouse bronchoalveolar
lavage fluid as measured by ELISA. (A) Anti-NGF antibody instilled one hour prior to ozone
exposure. (B) Anti-NGF antibody instilled two hours prior to ozone exposure. (C) Anti-NGF
antibody instilled four hours before exposure. Saline, n=4, Anti-NGF, n=5 for all experiments.
Values are means ± SE. * Significant difference between treated and untreated animals, P = 0.01.
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V. DISCUSSION
Ozone is an ubiquitous air pollutant and has been shown to cause numerous respiratory
effects (Lippmann, 1989; Beckett, 1991). Of these effects, airway inflammation and AHR are
the hallmark pulmonary characteristics of ozone exposure. This has been observed in animal
models and humans. For example, human subjects who show sensitivity to ozone exposure have
bronchial hyperresponsiveness to methacholine challenge not observed in non-sensitive subjects
(Hackney et al., 1989; Aris et al., 1991). Asthmatics had increased inflammation markers in
nasal lavage fluid after low level ozone challenge (0.12-0.24 ppm) when compared to nonasthmatic control subjects (McBride et al., 1994). The precise mechanism by which ozone
exposure causes AHR has not yet been fully elucidated, but previous work has suggested that the
airway inflammation seen after ozone exposure is an underlying cause. The current study
specifically investigates a possible signaling pathway responsible for translating ozone exposure
to airway inflammation through the release of a sensory neuropeptide, substance P, a mediator
proven to mediate neurogenic inflammation in the airways (Lundberg et al., 1983).
The study demonstrates in vivo that ozone exposure significantly increases the
concentrations of IL-1, NGF, and SP in mouse BALF. All three of these mediators have
previously been shown to promote airway inflammation, consistent with other animal models of
ozone exposure and epidemiological studies (Barnes et al., 2001; Park et al., 2004; Johnson et
al., 2005; Woolf, et al, 1994; Braun et al., 1998; Nassenstein, et al, 2004; Bachar, et al, 2004; de
Vries, et al 2006; Lee et al., 1979; Koto et al., 1995; Joad et al., 1996; Wu et al., 1997; Graham et
al., 2001).
The results showing IL-1 as a key modulator of SP levels in BALF are consistent with
our previous in vivo and in vitro reports in ferret (Wu et al., 2001, 2003) which showed that IL-1
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released after ozone exposure enhances airway responsiveness by modulating SP levels. This
present study further confirms the role of IL-1 as a key intermediate signaling molecule in the
downstream effects of ozone exposure by showing its modulatory effects on NGF. Previous
research has shown that IL-1 can modulate NGF expression in vitro (Olgart and Frossard, 2001;
Pons, et al, 2001; Freund et al., 2002) and increased levels of NGF has been reported in humans,
in vivo, in situations where IL-1 β is increased, particularly in asthma (Bonini et al., 1996; Olgart
et al., 2002; Virchow et al., 1998; Kassel et al., 2001). However, this study is the first report
demonstrating the direct manipulation of in vivo NGF levels via IL-1, whether exogenously
applied or by blockade of the ozone-induced increase of endogenous IL-1.
This study fails in proving NGF is a key mediator of ozone-induced increases in SP, but
only in the sense of NGF’s action through the TrkA receptor. The inability of K252a or antiNGF to decrease SP concentration in mouse BALF could be dependent upon the method of
blocking NGF effects. K252a blocks the tyrosine kinase pathway and the NGF antibody
decreases NGF binding to receptors. However, neither of these approaches would affect the SP
already present in neurons that would be released during ozone exposure. Another possibility is
that SP release could occur through an IL-1 related pathway not involving NGF or the release of
unrelated mediators such as TRPV1 ligands, bradykinin, or leukotrienes (Carr and Undem,
2001).
NGF is classified as a neurotrophin but there is increasing evidence suggesting it is
involved in a variety of immune functions. NGF has even been implicated as an asthma
mediator but direct evidence of inhibiting or blocking NGF induced effects is insufficient,
especially in vivo. Adding to this, the source and regulation of NGF expression in airways is not
fully understood, but a direct action of NGF on neurons may be part of this response since NGF
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increases the number of neurons and neuropeptide content in airways (Adler et al., 1984; Lindsay
and Harmar, 1989; Vedder et al., 1993; Cho et al., 1995; Hoyle et al., 1998; Malcangio et al.,
2000; Hunter et al., 2000; Skoff et al., 2003).
Although most of the data to this point suggests that TrkA mediates the majority of NGF
effects, there is growing evidence that p75 is more important than first thought in cellular
response to injury. For example, it has been shown that the p75 receptor modulates the NGF
excitation of adult rat nociceptive neurons (Zhang and Nicol, 2004). Peripheral tissue
inflammation increased p75 mRNA levels in dorsal root ganglia of rats while TrkA mRNA
levels remained the same (Cho et al., 1996). Intrathecal infusion of NGF into adult dorsal root
ganglia increases the concentration of p75 receptors but not TrkA receptors (Verge et al., 1989).
Additionally, local application of NGF in the iris increased p75 mRNA in sympathetic neurons
but had no effect on TrkA expression (Miller et al., 1994). Studies with NGF-over expressing
mice and p75-NTR knockout mice show that NGF effects are partly mediated by the p75
receptor in allergic airway and enhance the severity of the local inflammatory response
(Lommatzsch et al., 2003). Furthermore, Skoff and Adler (2006) demonstrated that in vitro NGF
up-regulation of SP expression in adult rat dorsal root ganglia sensory neurons requires both the
p75 and TrkA receptors. Even though they did not demonstrate the specific contribution of each
to the SP increase, they were able to show that blockade of the p75 receptor markedly reduces SP
expression. Obviously, the role this receptor has in ozone-induced increases of SP in mouse
BALF needs to be investigated before NGF can be ruled out as a key mediator in the proposed
transduction pathway.
In conclusion, this study demonstrates that ozone increases the concentrations of all three
proteins in mouse BALF, and that IL-1 is a key in vivo mediator of the ozone-induced increases
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of NGF and SP in mouse BALF. NGF may be a mediator of the ozone-induced increase of SP
but these results raise the possibility that a pathway other than the TrkA receptor may transduce
ozone mediated signaling through NGF. Further studies involving the precise role the p75
receptor has in this proposed mechanism are needed and could include the blockade of the p75
receptor before ozone exposure or by exposing p75-NTR knockout mice to ozone, then
measuring the level of SP in the BALF. These studies may provide the pertinent information for
solidifying this inflammatory-neuronal cascade.
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